6yg9: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='6yg9' size='340' side='right'caption='[[6yg9]], [[Resolution|resolution]] 1.89Å' scene=''> | <StructureSection load='6yg9' size='340' side='right'caption='[[6yg9]], [[Resolution|resolution]] 1.89Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'> | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6YG9 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6YG9 FirstGlance]. <br> | ||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.89Å</td></tr> | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.89Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=MYR:MYRISTIC+ACID'>MYR</scene>, <scene name='pdbligand=OQ5:20-[[(2~{S})-5-[2-[2-[2-[2-[2-[2-(diethylamino)-2-oxidanylidene-ethoxy]ethoxy]ethylamino]-2-oxidanylidene-ethoxy]ethoxy]ethylamino]-1-oxidanyl-1,5-bis(oxidanylidene)pentan-2-yl]amino]-20-oxidanylidene-icosanoic+acid'>OQ5</scene></td></tr> | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=MYR:MYRISTIC+ACID'>MYR</scene>, <scene name='pdbligand=OQ5:20-[[(2~{S})-5-[2-[2-[2-[2-[2-[2-(diethylamino)-2-oxidanylidene-ethoxy]ethoxy]ethylamino]-2-oxidanylidene-ethoxy]ethoxy]ethylamino]-1-oxidanyl-1,5-bis(oxidanylidene)pentan-2-yl]amino]-20-oxidanylidene-icosanoic+acid'>OQ5</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6yg9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6yg9 OCA], [https://pdbe.org/6yg9 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6yg9 RCSB], [https://www.ebi.ac.uk/pdbsum/6yg9 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6yg9 ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6yg9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6yg9 OCA], [https://pdbe.org/6yg9 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6yg9 RCSB], [https://www.ebi.ac.uk/pdbsum/6yg9 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6yg9 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | |||
Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease that can lead to irreversible liver cirrhosis and cancer. Early diagnosis of NASH is vital to detect disease before it becomes life-threatening, yet noninvasively differentiating NASH from simple steatosis is challenging. Herein, bifunctional probes have been developed that target the hepatocyte-specific asialoglycoprotein receptor (ASGPR), the expression of which decreases during NASH progression. The results show that the probes allow longitudinal, noninvasive monitoring of ASGPR levels by positron emission tomography in the newly developed rat model of NASH. The probes open new possibilities for research into early diagnosis of NASH and development of drugs to slow or reverse its progression. | |||
Triantennary GalNAc Molecular Imaging Probes for Monitoring Hepatocyte Function in a Rat Model of Nonalcoholic Steatohepatitis.,Mishra A, Castaneda TR, Bader E, Elshorst B, Cummings S, Scherer P, Bangari DS, Loewe C, Schreuder H, Poverlein C, Helms M, Jones S, Zech G, Licher T, Wagner M, Schudok M, de Hoop M, Plowright AT, Atzrodt J, Kannt A, Laitinen I, Derdau V Adv Sci (Weinh). 2020 Nov 9;7(24):2002997. doi: 10.1002/advs.202002997., eCollection 2020 Dec. PMID:33344141<ref>PMID:33344141</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 6yg9" style="background-color:#fffaf0;"></div> | |||
==See Also== | ==See Also== | ||
| Line 19: | Line 24: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Liesum A]] | [[Category: Liesum A]] | ||
[[Category: Schreuder HA]] | [[Category: Schreuder HA]] | ||
Latest revision as of 12:17, 9 October 2024
CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN (HSA) IN COMPLEX WITH GN-07.CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN (HSA) IN COMPLEX WITH GN-07.
Structural highlights
Publication Abstract from PubMedNonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease that can lead to irreversible liver cirrhosis and cancer. Early diagnosis of NASH is vital to detect disease before it becomes life-threatening, yet noninvasively differentiating NASH from simple steatosis is challenging. Herein, bifunctional probes have been developed that target the hepatocyte-specific asialoglycoprotein receptor (ASGPR), the expression of which decreases during NASH progression. The results show that the probes allow longitudinal, noninvasive monitoring of ASGPR levels by positron emission tomography in the newly developed rat model of NASH. The probes open new possibilities for research into early diagnosis of NASH and development of drugs to slow or reverse its progression. Triantennary GalNAc Molecular Imaging Probes for Monitoring Hepatocyte Function in a Rat Model of Nonalcoholic Steatohepatitis.,Mishra A, Castaneda TR, Bader E, Elshorst B, Cummings S, Scherer P, Bangari DS, Loewe C, Schreuder H, Poverlein C, Helms M, Jones S, Zech G, Licher T, Wagner M, Schudok M, de Hoop M, Plowright AT, Atzrodt J, Kannt A, Laitinen I, Derdau V Adv Sci (Weinh). 2020 Nov 9;7(24):2002997. doi: 10.1002/advs.202002997., eCollection 2020 Dec. PMID:33344141[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||